A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants

@article{Moya2005AMR,
  title={A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants},
  author={Fernando R. Moya and Janusz Gadzinowski and Eduardo Bancalari and Vicente Salinas and Benjamin Kopelman and Aldo Bancalari and Maria Katarzyna Kornacka and Thurman Allen Merritt and Robert Segal and Christopher J Schaber and Huei Tsai and Joseph M. Massaro and Ralph A. D’Agostino},
  journal={Pediatrics},
  year={2005},
  volume={115},
  pages={1018 - 1029}
}
Background and Objective. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that mimic the action of human surfactant protein-B (SP-B). A synthetic surfactant containing a mimic of SP-B may also reduce the potential risks associated with the use of animal-derived products. Our objective was to compare the efficacy and safety of a novel synthetic surfactant containing a functional SP-B mimic… 

Figures and Tables from this paper

A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure
  • N. Thomas, C. Guardia, A. Randolph
  • Medicine
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
  • 2012
TLDR
An improvement in oxygenation and a significantly reduced requirement for retreatment suggests that lucinactant might improve lung function in infants with acute hypoxemic respiratory failure, and treatment with intratracheal lucinactsant appeared to be generally safe.
Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials
  • F. Moya
  • Medicine
    Journal of Perinatology
  • 2009
TLDR
Findings from trials of a new-generation synthetic surfactant containing a peptide that mimics SP-B suggest that its administration improves short-term clinical outcomes compared with colfosceril and results in survival through 1 year of age, which is at least comparable, if not perhaps superior, to that seen with animal-derived surfactants.
Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
TLDR
This review considers studies that enrolled preterm infants or low birth weight infants at risk for or having RDS who were treated with either a synthetic surfactant containing surfactants protein mimics or a protein free synthetic Surfactant, and found no statistically different clinical differences in death and chronic lung disease.
A comparative pharmacoeconomic assessment of two surfactants for the prevention of respiratory distress syndrome.
TLDR
This comprehensive pharmacoeconomic analysis indicates that lucinactant is a cost-effective therapy for the prevention of RDS among preterm infants.
Lucinactant (Surfaxin ™ ) for prevention and treatment of respiratory distress syndrome in newborns
TLDR
Synthetic surfactants, such as lucinactant (Surfaxin™, Discovery Laboratories, PA, USA), which contains the protein B mimic synthetic peptide, sinapultide, are being developed.
Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future
TLDR
Novel synthetic surfactants containing synthetic phospholipid incorporated with SP-B and SP-C analogs will potentially represent alternatives to natural Surfactants in the future, while improvement of treatment modalities with less-invasive or noninvasive methods of surfactant administration will be the most important task to be resolved.
Lucinactant: A new solution in treating neonatal respiratory distress syndrome NRDS
TLDR
Lucinactant is a novel synthetic surfactant, approved by the FDA on March 6 th 2012, for use in treatment of RDS and has shown immense efficacy in phase two clinical trials and animal model studies and exhibited better efficiency when compared to other surfactants in both 24 hour and two week mortality rates of infants in RDS.
Acute and Sustained Effects of Lucinactant Versus Poractant-α on Pulmonary Gas Exchange and Mechanics in Premature Lambs With Respiratory Distress Syndrome
TLDR
Among preterm lambs with severe RDS, lucinactant produced improvements in gas exchange and lung mechanics similar to those observed with a porcine-derived surfactant, with no differences between groups.
Lucinactant for the treatment of respiratory distress syndrome in neonates.
TLDR
The clinical trials that have been performed, although underpowered, may indicate that lucinactant is superior to phospholipid synthetic surfactant preparations and at least as effective as animal-derived surfactants in reducing morbidity and mortality from RDS.
Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
TLDR
In a meta-analysis of two studies, infants who received protein containing synthetic surfactants compared to animal derived surfactant extract did not demonstrate significantly different risks of prespecified primary outcomes, and well designed studies of adequate size and power will be needed to confirm and refine these findings.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome
TLDR
Lucinactant and poractant alfa were similar in terms of efficacy and safety when used for the prevention and treatment of RDS among preterm infants, with the lower boundary of the 95% CI for the difference being greater than the prespecified noninferiority margin.
A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
TLDR
Treatment with Infasurf resulted in significant improvement in several secondary outcome measures and is suggested that a more effective surfactant is a better option than Exosurf in the prevention of neonatal respiratory distress syndrome.
A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome
TLDR
Although no differences were noted between Survanta- and Exosurf-treated infants regarding the primary outcome of death or chronic lung disease at 28 days of age, the significant improvement in secondary clinical outcomes suggests that SurvantA is more effective than ExosURf Neonatal in the treatment of established RDS.
Efficacy of Synthetic Peptide-Containing Surfactant in the Treatment of Respiratory Distress Syndrome in Preterm Infant Rhesus Monkeys
TLDR
The importance of the peptide in the synthetic surfactant was apparent, and animals treated with a dose of 200 mg/kg showed a faster, more consistent, and greater response than did a group treated with an average dose of 127mg/kg.
Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants.
  • R. Soll
  • Medicine
    The Cochrane database of systematic reviews
  • 2000
TLDR
Significant differences were seen in the risk of intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity and cerebral palsy, while infants who receive prophylactic synthetic surfactant have an increased risk of developing patent ductus arteriosus and pulmonary hemorrhage.
Bronchoalveolar Lavage Surfactant Protein A, B, and D Concentrations in Preterm Infants Ventilated for Respiratory Distress Syndrome Receiving Natural and Synthetic Surfactants
TLDR
BAL SP concentrations did not differ significantly between infants randomized to receive a natural or synthetic surfactant, and lower BAL SP-B and SP-D but not SP-A concentrations were associated with worse clinical prognosis.
The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome.
TLDR
Data demonstrate that the synthetic peptide, KL4, which mimics the hydrophobic and hydrophilic pattern of SP-B, when formulated in an aqueous dispersion with the phospholipids DPPC and POPG, creates a strong and durable surfactant activity as judged by expansion of pulmonary alveoli and improvement of gas exchange in infants with RDS.
Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome.
TLDR
Comparative trials demonstrate greater early improvement in the requirement for ventilator support, fewer pneumothoraces, and fewer deaths associated with natural surfactant extract treatment, as well as a marginal decrease in the risk of bronchopulmonary dysplasia or mortality associated with the use of natural surfACTant preparations.
Experimental Neonatal Respiratory Failure Induced by a Monoclonal Antibody to the Hydrophobic Surfactant-Associated Protein SP-B
TLDR
The data suggest that the MAb to SP-B inhibits surfactant function in the neonatal period by blocking one of the mechanisms responsible for fast adsorption of the surfactants phospholipids to the alveolar air-liquid interface.
...
1
2
3
4
5
...